ComplyRx

Antibody-drug conjugates · Live ClinicalTrials.gov data

Datopotamab deruxtecan (Datroway) clinical trial pipeline

The timeline below tracks the 16 largest phase 2–4 datopotamab deruxtecan (Datroway) trials on ClinicalTrials.gov by enrolment, 8 of them actively recruiting. The next phase 3 primary completion among them is expected Sept 2026. Refreshed daily. Add up to four competitors to compare pipelines side by side.

16+

Major trials tracked

13

Phase 3 trials

8

Actively recruiting

Sept 2026

Next phase 3 primary completion

18,118

Participants across trials

AstraZeneca

Lead sponsor by trial count

datopotamab deruxtecan (16)16 active2010–2032
datopotamab deruxtecan
Key
Actual date
Anticipated
Forecast to primary completion
RecruitingActive, not recruiting
'10
'12
'14
'16
'18
'20
'22
'24
'26
'28
'30
'32
datopotamab deruxtecan
I-SPYP2
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)P3
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)P3
TROPION-Lung08P3
NeoCOAST-2P2
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)P3
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)P3
AVANZARP3
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)P3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerP3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)P3
TROPION-Lung10P3
TROPION-Lung14P3
TROPION-Lung15P3
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaP2
TU-04P3

Upcoming readouts

13 ahead · datopotamab deruxtecan

Select a trial to load its full ClinicalTrials.gov record.

Key datopotamab deruxtecan trials

Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.

TrialTitlePhaseStatusPrimary completion
NCT06417814TROPION-Lung15: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared …Phase 3RecruitingSept 2026
NCT06103864A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of …Phase 3RecruitingJul 2027
NCT06350097TROPION-Lung14: Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for…Phase 3RecruitingMar 2028
NCT06357533TROPION-Lung10: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanc…Phase 3RecruitingDec 2029
NCT07720284TU-04: An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in…Phase 3RecruitingSept 2030
NCT04656652Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell L…Phase 3Active, not recruitingMay 2024
NCT05104866A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy…Phase 3Active, not recruitingJul 2024
NCT05374512A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent…Phase 3Active, not recruitingAug 2025
NCT05629585A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patien…Phase 3Active, not recruitingSept 2027
NCT05687266AVANZAR: Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplat…Phase 3Active, not recruitingNov 2027
NCT06112379A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatm…Phase 3Active, not recruitingNov 2028
NCT05555732Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L …Phase 3Active, not recruitingMay 2029

Track datopotamab deruxtecan with ComplyRx

Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.

Track datopotamab deruxtecan

Related drug pipelines

Compare datopotamab deruxtecan vs trastuzumab deruxtecanCompare datopotamab deruxtecan vs sacituzumab govitecan

FAQ

How many clinical trials are running for datopotamab deruxtecan?
ClinicalTrials.gov lists more than 16 phase 2–4 datopotamab deruxtecan trials. This page tracks the 16 largest by enrolment: 3 phase 2, 13 phase 3, and 0 phase 4 among them, with 8 actively recruiting. Updated daily.
Are there clinical trials for Datroway?
Datroway is the brand name for datopotamab deruxtecan, so datopotamab deruxtecan trials on ClinicalTrials.gov cover it. ClinicalTrials.gov lists more than 16 phase 2–4 datopotamab deruxtecan trials. This page tracks the 16 largest by enrolment: 3 phase 2, 13 phase 3, and 0 phase 4 among them, with 8 actively recruiting. Updated daily.
Where does this data come from?
All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
Can I compare datopotamab deruxtecan against other drugs?
Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.